drugset / Trial / NCT00346047

Comparison of BTDS (Buprenorphine Transdermal System) and Placebo in Low Back Pain

NCT00346047

Phase 3 Completed 238 enrolled Mundipharma K.K.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy and safety of BTDS compared to placebo in subjects with moderate to severe low back pain.

Timeline

Start
2006-05
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 5 mg Other
Subject Buprenorphine Other / unclassified 10 mg Other
Subject Buprenorphine Other / unclassified 20 mg Other

Indications

No indication recorded.